ORPN - Bioblast Pharma Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9601
-0.0799 (-7.68%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.0400
Open1.0200
Bid0.9600 x 800
Ask1.0400 x 900
Day's Range0.9600 - 1.0500
52 Week Range0.7740 - 3.7500
Volume3,417
Avg. Volume103,355
Market Cap3.225M
Beta (3Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-0.9950
Earnings DateFeb 22, 2018 - Feb 26, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Bioblast Pharma Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Non-Compliance

    Bioblast Pharma Ltd. (ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written notification from the Listing Qualifications Department of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that Nasdaq has determined that Bioblast’s stockholders’ equity does not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(1).

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Auris Medical and Bioblast Pharma

    NEW YORK, NY / ACCESSWIRE / November 21, 2018 / It was a day of gains for biotech stocks Auris Medical Holding and Bioblast Pharma after the companies announced positive developments. Bioblast announced it has executed a definitive agreement to acquire Enlivex Therapeutics while Auris Medical announced the results of a Pre-IND meeting with the FDA. Auris Medical Holding AG shares were up nearly 36% on Tuesday on roughly 13.7 million shares traded.

  • ACCESSWIRE2 months ago

    New Healthcare Trends Have Investors Looking at 4 Stocks

    Heading into the holiday week, a number of healthcare names are taking hold of a bull market in healthcare stocks. HealthVue currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.

  • GlobeNewswire2 months ago

    Bioblast Pharma Ltd. Announces Entry Into Merger Agreement to Acquire Enlivex Therapeutics Ltd. to Advance Clinical Stage Immunotherapeutic Drug Pipeline for the Treatment of Life-Threatening Diseases Sepsis, GvHD and Solid Tumors

    Enlivex is developing a novel immunotherapy with a unique mode of action targeting clinical indications defined as “life-threatening, unmet medical need,” such as preventing or treating complications associated with bone-marrow transplantations, sepsis – which is the third-leading cause of mortality in the U.S. after cardiovascular and cancer diseases, as well as effective treatment of solid tumors via immune checkpoint reprogramming, increasing the efficacy of CAR-T, TCR and other anti-cancer therapies. Phase IIa clinical trial for the prevention of GvHD in matched-donor population successfully completed.  Initiation of Phase II clinical trial in sepsis expected in Q2-2019, and initiation of a Phase II clinical trial for treatment of steroid-refractory GvHD patients and a Phase II/III clinical trial for preventing GvHD in bone marrow transplantations are expected in Q4-2019.

  • Who Are The Top Investors In Bioblast Pharma Ltd (NASDAQ:ORPN)?
    Simply Wall St.8 months ago

    Who Are The Top Investors In Bioblast Pharma Ltd (NASDAQ:ORPN)?

    Today, I will be analyzing Bioblast Pharma Ltd’s (NASDAQ:ORPN) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, theRead More...

  • Benzinga9 months ago

    Benzinga Pro's 6 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! athenahealth, Inc (NASDAQ: ATHN ) stock was trading ...

  • What Kind Of Risk Should You Expect For Bioblast Pharma Ltd (NASDAQ:ORPN)?
    Simply Wall St.9 months ago

    What Kind Of Risk Should You Expect For Bioblast Pharma Ltd (NASDAQ:ORPN)?

    If you are looking to invest in Bioblast Pharma Ltd’s (NASDAQ:ORPN), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • Should You Be Concerned About Bioblast Pharma Ltd’s (NASDAQ:ORPN) Investors?
    Simply Wall St.11 months ago

    Should You Be Concerned About Bioblast Pharma Ltd’s (NASDAQ:ORPN) Investors?

    I am going to take a deep dive into Bioblast Pharma Ltd’s (NASDAQ:ORPN) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structureRead More...